EU/3/10/748: Orphan designation for the treatment of Hutchinson-Gilford progeria

Pravastatin / zoledronic acid

Table of contents


On 9 June 2010, orphan designation (EU/3/10/748) was granted by the European Commission to Prenyl BIO SAS, France, for pravastatin / zoledronic acid for the treatment of Hutchinson-Gilford progeria.

Key facts

Active substance
  • Pravastatin
  • zoledronic acid
Intended use
Treatment of Hutchinson-Gilford progeria
Orphan designation status
EU designation number
Date of designation
Prenyl BIO SAS
avenue Vacher CD6
Immeuble CCE
ZI de Rousset Peynier
13106 Rousset
Telephone: +33 491 25 40 46
Telefax: +33 486 95 81 00

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating